Halozyme Therapeutics, Inc. (HALO) vs Summit Therapeutics Inc. (SMMT)

A side-by-side comparison of Halozyme Therapeutics, Inc. and Summit Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Halozyme Therapeutics, Inc. logo
HALO
Halozyme Therapeutics, Inc.
$13.04B
$109.94HealthcareDelayed quote: Oct 6, 2026, 1:20 PM EDT
Summit Therapeutics Inc. logo
SMMT
Summit Therapeutics Inc.
$13.54B
$16.97HealthcareDelayed quote: Oct 6, 2026, 1:15 PM EDT

Total return — HALO vs SMMT

growth of $100 · dividends reinvested · last 10y
HALO +779.9% (+24.3%/yr)SMMT +99.7% (+7.2%/yr)HALO compounded faster over this window
0200400600800Start $10020182020202220242026$880$200
HALO SMMT

HALO vs SMMT: by the numbers

  • •SMMT is the larger company ($13.54B vs $13.04B market cap).
  • •HALO is profitable (24.86% net margin) while SMMT runs a net loss (0.00%).

Metrics side by side

Valuation

MetricHALOSMMT
P/E ratio32.82N/A
Forward P/E13.07N/A
PEG ratio1.43N/A
P/S ratio7.84N/A
P/B ratio90.8521.49
EV / EBITDA14.24N/A
FCF yield6.18%N/A

Profitability

MetricHALOSMMT
Gross margin78.18%0.00%
Operating margin56.77%0.00%
Net margin24.86%0.00%
ROE288.13%-135.89%
ROIC27.42%-134.14%

Growth (annualized)

MetricHALOSMMT
Revenue CAGR (5Y)32.18%N/A
EPS CAGR (5Y)22.68%N/A
FCF CAGR (5Y)40.08%N/A
Total return CAGR (5Y)22.18%28.09%

Frequently asked

Is HALO or SMMT more profitable?
HALO runs the higher net margin — HALO at 24.86% versus SMMT at 0.00%.
How have HALO and SMMT total returns compared?
Over the past 10 years, HALO delivered 24.30% and SMMT delivered 1.87% annualized total return. Past performance doesn't predict future results.

Go deeper

Full HALO analysisFull SMMT analysisInteractive comparison tool

Dig into the metrics

Halozyme Therapeutics P/E ratioHalozyme Therapeutics ROESummit Therapeutics ROEHalozyme Therapeutics operating marginSummit Therapeutics operating marginHalozyme Therapeutics revenue growthSummit Therapeutics revenue growthHalozyme Therapeutics free cash flowSummit Therapeutics free cash flow

Halozyme Therapeutics & Summit Therapeutics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksHighest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.